{
    "nct_id": "NCT04401748",
    "official_title": "A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)",
    "inclusion_criteria": "* Participants with a diagnosis of Myelodysplastic Syndrome (MDS) according to the 2016 World Health Organization (WHO) classification wtih presence of < 20% bone marrow blasts per marrow biopsy/aspirate at screening.\n* Participants must meet the following disease activity criteria:\n\n  * Overall Revised International Prognostic Scoring System (IPSS-R) score > 3 (intermediate, high or very high).\n  * Eastern Cooperative Oncology Group (ECOG) performance status of <= 2.\n  * Hematopoietic stem cell transplant (HSCT) eligible with no pre-arranged HSCT at the time of Study Day 1, or HSCT ineligible without plan for HSCT at the time of Study Day 1.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior therapy for MDS with any hypomethylating agent, chemotherapy, or allogenic stem cell transplantation.\n* Prior diagnosis of therapy-related MDS (t-MDS), MDS evolving from a pre-existing myeloproliferative neoplasm (MPN), MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.",
    "miscellaneous_criteria": ""
}